Literature DB >> 8931826

Upper gastrointestinal motility disorders and respiratory symptoms.

L R Schiller1.   

Abstract

The association between upper gastrointestinal (GI) motility disorders and respiratory problems is reviewed. Upper GI motility disorders, such as gastroesophageal reflux disease, gastroparesis, and achalasia, have been associated with respiratory problems, including aspiration, airway obstruction, asthma, bronchospasm, chronic cough, and laryngitis. These associations, which had been based solely on clinical observation, have recently been supported by physiologic studies and treatment trials. The association of reflux disease with asthma has the most support. Up to 80% of persons with asthma have evidence of pathologic gastroesophageal reflux, and in several studies antireflux therapy with prokinetic agents, antisecretory drugs, or fundoplication surgery has been found to reduce asthma symptoms and the need for medication in some patients. Reflux has also been associated with chronic cough and laryngitis, and antireflux therapy can reduce respiratory symptoms. Gastroesophageal reflux, gastroparesis, and achalasia are all associated with aspiration. In addition, in rare instances, the megaesophagus associated with achalasia can produce mechanical airway obstruction. Effective therapy for these GI motility disorders can eliminate complicating respiratory problems.

Entities:  

Mesh:

Year:  1996        PMID: 8931826     DOI: 10.1093/ajhp/53.22_Suppl_3.S13

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  2 in total

1.  [Stenosing gastric laryngitis in infancy].

Authors:  A Hennig; A Neumann; H-J Schultz-Coulon
Journal:  HNO       Date:  2004-04       Impact factor: 1.284

2.  Women's Respiratory Movements during Spontaneous Breathing and Physical Fitness: A Cross-Sectional, Correlational Study.

Authors:  Wen-Ming Liang; Zhen-Min Bai; Maiwulamu Aihemaiti; Lei Yuan; Zhi-Min Hong; Jing Xiao; Fei-Fei Ren; Osvaldas Rukšėnas
Journal:  Int J Environ Res Public Health       Date:  2022-09-22       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.